Literature DB >> 14684210

Equivalent cross relaxation rate image for decreasing a false negative case of sentinel lymph node biopsy.

Shigeru Matsushima1, Fumio Sasaki, Shuhei Sarumaru, Daisuke Ohta, Seiichi Era, Masaru Sogami, Tadashi Inaba, Yasutomi Kinosada.   

Abstract

In the breast carcinamas, sentinel lymph node biopsy (SLNB) attracts attention as technique to be settled by axillary lymph node metastasis, but existence of a false negative case is a problem. Equivalent cross relaxation rate image (ECRI) is the measurement method that we can evaluate a change of organization structure quantitatively by magnetic resonance imaging. We executed axillary ECRI as a purpose with decreasing a false negative case of SLNB. ECRI related to a macroscopic image, and it was possible to evaluate yes or no of axillary lymph node metastasis. ECRI is the useful method to evaluate adaptability of SLNB.

Entities:  

Mesh:

Year:  2003        PMID: 14684210     DOI: 10.1016/s0730-725x(03)00208-x

Source DB:  PubMed          Journal:  Magn Reson Imaging        ISSN: 0730-725X            Impact factor:   2.546


  3 in total

1.  Cellular density evaluation for malignant lymphoma using equivalent cross-relaxation rate imaging - initial experience.

Authors:  Hideyuki Nishiofuku; Shigeru Matsushima; Yoshitaka Inaba; Hidekazu Yamaura; Yozo Sato; Yasuo Morishima; Kimihiko Kichikawa
Journal:  Korean J Radiol       Date:  2010-04-29       Impact factor: 3.500

2.  Correlation between equivalent cross-relaxation rate and cellular density in soft tissue tumors.

Authors:  Shunsuke Hamada; Shigeru Matsushima; Hideshi Sugiura; Kenji Yamada; Yoshihiro Nishida; Naoki Ishiguro
Journal:  Skeletal Radiol       Date:  2013-11-20       Impact factor: 2.199

3.  Cellular Imaging Using Equivalent Cross-Relaxation Rate Technique in Rabbit VX-2 Tumor Model.

Authors:  Hideyuki Nishiofuku; Shigeru Matsushima; Osamu Taguchi; Yoshitaka Inaba; Hidekazu Yamaura; Yozo Sato; Toshihiro Tanaka; Kimihiko Kichikawa
Journal:  Cancer Inform       Date:  2011-08-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.